Mylan N.V. upped the ante Friday in its quest for Perrigo Co. with a $33 billion bid for the generic drug maker. The deal is worth or $60 in cash plus 2.2 Mylan shares for each Perrigo share. Mylan's earlier bid for the company was rejected just as Teva Pharmaceutical Industries made an offer for Mylan earlier this week. Teva is offering $40 billion for Mylan. The three generic drug makers are trying to consolidate as the industry undergoes a period of slowing growth.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below